• Copy number variations (CNV) involving the insulin-like growth factor 1 receptor gene (IGF1R) result in varying degrees of pre-and postnatal growth restriction.
Introduction
Normal human intrauterine and postnatal growth requires an intact insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF1R) axis. IGF1R haploinsufficiency due to molecular defects is associated with impaired growth and indicates that a single allele of the IGF1R gene is insufficient for normal growth and development. A complete loss of IGF1R has yet to be reported in humans, and may be lethal, as was shown in rodent studies in which targeted ablation of the Igf1r gene resulted in perinatal death [1, 2] . Indeed, for the most hypomorphic of IGF1R mutations described to date (2 homozygous missense mutations [3, 4] and 2 compound heterozygous IGF1R mutations [5, 6] ), residual expression and function likely ensured survival, although clinical presentations were more severe than in patients who were IGF1R haploinsufficient [7, 8] . Current treatment options of recombinant human (rh) GH or rhIGF-I therapy, approved for multiple indications including idiopathic short stature and small for gestational age (SGA), remain a conundrum, as IGF1R-deficient patients exhibit IGF-I resistance, often with serum IGF-I concentrations well above the normal ranges.
Synthesized as a single polypeptide precursor, the IGF1R undergoes proteolytic cleavage into α-and β-chains and forms a tetramer (α 2 β 2 ), with the extracellular α 2 -subunits involved in ligand binding and the intracellular β 2 -subunits carrying the intrinsic tyrosine kinase functions necessary for signal transduction [9] . Ligand association leads to IGF1R autophosphorylation and activation of multiple downstream signaling pathways, including the phosphatidylinositol 3-kinase/AKT and MAPK/ERK pathways important for cell survival and growth [10] . In an IGF1R haploinsufficiency state, IGF-Iinduced IGF1R signaling is reduced [11] [12] [13] , although binding of IGF-I may remain normal [14, 15] , further stressing the necessity of biallelic expression of the IGF1R gene for full biological activity.
In this study, we report 3 new IGF1R haploinsufficiency cases and highlight (a) the unique application of whole exome sequencing (WES) data for assessing copy number variation (CNV) in the genetic workup of short stature; (b) the utility of fluorescence-activated cell sorting (FACS) analysis as a promising method for efficiently evaluating cell-surface IGF1R availability using live primary cells derived from patients; and (c) the effectiveness of rhGH therapy for treating some patients. Our study expands the genetic and functional diagnosis for an IGF1R haploinsufficiency state, emphasizes the importance of including CNV analysis in the initial evaluation of children who present with clinical and biochemical features suggestive of IGF1R insufficiency, and raises questions of how comparable IGF1R availability results in variable clinical phenotypes and responsiveness to rhGH therapy.
Materials and Methods

Clinical Reports
Proband 1 Proband 1 (P1), an 8-year-old Chilean girl with short stature, was born at 35 weeks of gestation with a birth weight of 2.1 kg, and a birth length of 42 cm (SDS -2.61), to nonconsanguineous parents. She showed catch-up growth (to the 25th percentile for height) until the age of 5 years when she started to deviate below this channel. At the age of 8.3 years, her height was 115.5 cm (SDS -2.06), her weight was 22.1 kg (SDS -0.92), her body mass index was 16.3 (SDS +0.25), and her head circumference was 51 cm (SDS -1.0). The patient had proportional body segments and no dysmorphic features.
Her endocrine evaluations at the age of 8 years revealed elevated serum IGF-I (488 ng/mL, reference range [RR], 120-385) and serum IGFBP-3 (6.2 mg/L, RR, 2.2-6.5) for her prepubertal, chronological age. Her basal serum GH was 1.1 ng/L, which peaked at 11.2 ng/L after stimulation with clonidine. A diagnosis of IGF-I insensitivity was made.
During this period, rhGH therapy starting at a relatively low dose of 0.117 mg/kg/week led to a clinically significant increase in her growth velocity. During rhGH treatment, her height shifted from below the 3rd percentile to approximately the 10th percentile at 12 years of age (Fig. 1a) . As expected, her serum IGF-I concen-DOI: 10.1159/000464143 trations on rhGH therapy were high (811-1,145 ng/mL). Her pubertal development advanced normally, and she underwent menarche at 12.5 years of age.
Her family history revealed that her father is modestly short, with a height of 163 cm (SDS -1.93), whereas her mother's height is normal (157 cm, SDS -0.98) as is her 18-year-old brother's height (168 cm, SDS -1.2). A summary of the endocrine studies for P1 is shown in Table 1. Proband 2 Proband 2 (P2) is an 8-year-old Caucasian boy with neurofibromatosis type 1 (NF-1) who presented with severe growth failure. He was born SGA at 36 weeks with a birth weight of 1.930 kg (SDS -2.25), a birth length of 43.2 cm (SDS -2.3), and a head circumference of 32.5 cm (SDS -1.5). His growth chart is shown in Figure 1b . He required therapy for mild motor and language delays in the toddler years. His brain magnetic resonance imaging showed a stable lesion (likely a glioma) in the left inferior cerebellar peduncle, with normal pituitary and optic nerve tracts.
The initial endocrine evaluations (Table 1) showed slow weight gain (SDS -2.5), growth failure (SDS -3.4), and mild microcephaly (head circumference SDS -2.0). Physical examination showed café-au-lait spots, a thin upper lip, fifth finger clinodactyly, and subcutaneous neurofibromas. His development was age appropriate; only symptoms of attention deficit and hyperactivity were observed.
His endocrine evaluation at the age of 8 years revealed serum IGF-I of 161 ng/mL and serum IGFBP-3 of 4.03 mg/L, both normal for his chronological age. His GH-binding protein was 916 pmol/L; acid labile subunit was 8.8 mg/L and thyroxine was 2.1 ng/dL, all within the normal range. His serum GH peaked at 15.5 ng/mL after stimulation with arginine/clonidine.
His family history revealed that his maternal grandmother is modestly short, with a height of 152 cm (SDS -1.8), whereas his paternal grandparents are normal statured. His mother, who also has NF-1, has a normal height of 160 cm (SDS -0.5) and his father's height is 178 cm (SDS 0.2). Clinical data for P2 are shown in Table 1 .
Proband 3
Proband 3 (P3) is a 6-year-old Chinese girl with severe postnatal growth failure. She was born SGA from a term delivery with a birth weight of 1.65 kg (SDS -3.0); her birth length was not recorded. She underwent repair of a ventricular septal defect and an aortic coarctation in the neonatal period. She did not speak until the age of 3 years and was subsequently diagnosed with a central auditory processing disorder.
Her initial endocrine evaluation showed that her height was -5.2 SDS and her weight -5 SDS. The physical examination showed mild mid-face hypoplasia, crowded dentition, and ocular hypertelorism. Her serum IGF-I was 296 ng/mL (RR, 52-297) and IGFBP-3 was normal. GH stimulation test with clonidine peaked at 35 ng/mL.
During this period, rhGH therapy was started at a dose of 0.30 mg/kg/week (Fig. 1c) . From the age of 6.3 to 9.5 years, her height improved to -4.1 SDS with persistently elevated IGF-I and IGFBP-3 concentrations. rhGH was discontinued at the age of 10 years after growth failed to improve on a higher rhGH dose of 0.42 mg/kg/ week, despite an elevated serum IGF-I concentration of 709 ng/mL (RR, 65-457) and an IGFBP-3 of 6.5 mg/L (RR, 2.9-5.2). At the age of 12.8 years, she had Tanner 2 breast and Tanner 3 pubic hair, irregular menses, a bone age of 13 years, and an improved growth rate of 7.1 cm/year off rhGH, with a markedly high serum IGF-I concentration of 1,183 ng/mL. At the age of 14.2 years, her height Table 1 .
Her family history revealed that her father's height is normal at 170 cm (SDS -0.2) and her mother's height is also normal (163 cm, SDS -0.2). She has 1 sister, also reported with normal linear growth.
Samples from Probands and Family Members
Blood samples from the probands and all immediate family members were collected for genetic studies with informed consent and in compliance with the respective institutional review boards. Serum assays for P1 were performed by standard techniques in the IDIMI laboratory. Serum IGFBP-3 was measured by an immunoradiometric assay from Diagnostic System Laboratories (Webster, TX, USA). Serum assays for P2 and P3 were measured as previously described [11] .
Primary Dermal Fibroblast Cell Cultures
Primary fibroblast cultures were established from skin biopsies taken from the forearm of the index patients (P1, P2) and from a control subject with normal pre-and postnatal growth. Samples were collected in compliance with the study protocol approved by the institutional review boards of San Borja-Arriarán Clinical Hospital, Cincinnati Children's Hospital Medical Center, and Oregon Health & Science University. Fibroblast cultures were maintained as previously described [11] .
Genomic DNA and cDNA Extraction of genomic DNA from whole blood or primary fibroblast cultures, total RNA from primary fibroblast cultures, synthesis of cDNA, and Sanger sequencing of the IGF1R gene have been previously described [11] . The primers for PCR amplification of exon 13 are as follows: forward, 5′-GCCAAGGGTGTGGT-GAAAGATGAA-3′; reverse, 5′-ACCACATGGTGACAATTGAA-CTCCTTCATC-3′.
Fluorescence in situ Hybridization Analysis
The RP11-602 fluorescence in situ hybridization (FISH) probe and standard cytogenetic techniques were used to confirm the deletion observed in P2.
Chromosomal Microarray
Single nucleotide polymorphism (SNP) microarray analysis was performed on genomic DNA samples from P2. The Illumina Infinium assay was performed on DNA samples using the Cyto-SNP-850K BeadChip platform. B-allele frequency and Log2R ratio were analyzed with the Illumina GenomeStudio analysis software, and DNA copy number changes were prioritized using cnvParti- Whole Exome Sequencing WES was performed on DNA extracted from whole blood from P3 and her parents. After library construction, hybridization and capture were performed using the Illumina's Rapid Capture Exome Kit and following the manufacturer's suggested protocol. Sequencing, downstream sequence alignment, variant calling, and variant annotation were performed as previously described [16] . Exomes were sequenced with mean target coverage >80X. Variants were then filtered for rare (minor allele frequency <1%) nonsynonymous variants that segregated with the phenotype as previously described [16] . CNV was called using the eXome-Hidden Markov Model (XHMM) algorithm [17] using default parameters and adjustment for the first 5 principal components. CNV were jointly called and genotyped along with 189 additional samples sequenced on the same platform, including samples from the parents of P3.
Flow Cytometry Analysis by FACS
Flow cytometric analysis by FACS of cell-surface IGF1R on live primary fibroblasts was performed (for detailed procedure, see online suppl. Methods; see www.karger.com/doi/10.1159/000464143 for all online suppl. material). Briefly, adherent fibroblasts were gently lifted with 0.05% trypsin/5 mM EDTA after IGF-I treatment (100 ng/mL, 24 h), trypsin activity were neutralized with fetal bovine serum supplemented media, and RPMI-washed suspended cells in aliquots of 100 µL (10 6 cells/mL RPMI) were processed for FACS analysis as for PBMCs (see below). All experiments were performed in triplicates, at least 2 independent times.
PBMCs were prepared for FACS of cell-surface IGF1R [18] . Briefly, cells, treated for 1 h with or without 50 ng/mL IGF-I (GroPep Ltd, Thebarton, SA, Australia), were incubated with phycoerythrin (PE)-conjugated anti-human IGF1R-α (CD221; BD Biosciences, San Jose, CA, USA) for 30 min (4 ° C in the dark), and stained with 0.25% propidium iodide (PI). For each sample, a total of 100,000 live PBMCs or 20,000 live fibroblasts (PI-negative cells) were acquired via a FACSCalibur flow cytometer (BD Biosciences), and the fluorescence emitted by IGF1R-PE-labeled cells (gated as shown in online suppl. Fig. 1 ) was analyzed using FCS Express 3 analysis software (De Novo Software, Los Angeles, CA, USA).
Western Immunoblot Analysis
Cultured fibroblasts were serum starved overnight prior to IGF-I treatment (15 or 20 min), cell lysates collected and subject to Western immunoblot analyses [19] . Rabbit polyclonal IgG against phospho-AKT (dilution 1: 1,000) and rabbit monoclonal IgG against Akt (dilution 1: 2,000) were purchased from Cell Signaling Technologies (Beverly, MA, USA). The anti-rabbit IgG secondary antibody was purchased from Amersham-Pharmacia Biotech (Uppsala, Sweden).
Results
Identification of Novel Heterozygous IGF1R Variants
Clinical and biochemical profiles of the 3 probands were consistent with resistance to the growth-promoting effects of IGF-I. Defective IGF1R expression was considered. Targeted sequencing of the IGF1R gene of genomic DNA (whole blood or cultured fibroblasts) from P1 identified a heterozygous IGF1R c.2629C>T variant (rs150221450; minor allele frequency of 8.237e-06, Exome Aggregation Consortium Browser) in exon 13 (Fig. 2a) , a transition variant confirmed in Sanger sequencing of the IGF1R cDNA. Analysis of the genomic DNA from the other family members revealed that the father was also heterozygous for c.2629C>T. The c2629C>T changed codon Arg877 (CGA) to a stop codon (TGA), p.R877*, generating a predicted truncated IGF1R protein which, if expressed, would be unable to anchor to the cell membrane.
In contrast to P1, P2 and P3 were found to carry CNV of IGF1R. For P2, SNP microarray analysis identified an unique heterozygous interstitial deletion of approximately 0. (Fig. 2b) , the deletion of which resulted in loss of ∼75% of the IGF1R-coding sequences, in addition to 3 other genes that have unknown phenotypic effects (PGPEP1L, SYNM, and TTC23). Parental study of chromosome 15q26.3 by FISH analysis confirmed a maternally inherited deletion (Fig. 2b) .
The IGF1R CNV in P3 was identified through re-evaluating WES data for CNV, an analysis procedure not routinely performed with WES. Initial analysis of WES (P3 and parents) utilizing stringent filtering of called rare variants did not reveal an obvious genetic cause for the phenotypic presentation. Analysis was subsequently expanded to CNV discovery, applying the XHMM algorithm [17] . A total of 27 CNV (16 deletions and 11 duplications) were successfully detected in the patient's sample, including a large 4.492-Mb heterozygous deletion on chromosome 15 [46 XX del(15)(q26.2:qter)(97,970,832-102,463,314)] (Fig. 2c) . The CNV was not present in either the parents, or in the 189 additional exomes that were simultaneously analyzed, suggesting that the 4.492-Mb deletion was de novo in P3. All other CNV were either inherited from the parents and/or were present in additional individuals in the CNV call set. plex phenotype, a database search of each gene for functions and association with diseases (OMIM, PubMed, and UniProt) supports deletion of IGF1R as the primary contributor. Of note, no other rare protein-altering sequence variants in IGF1R were identified. P3 was treated with rhGH and demonstrated only a modest growth response to GH therapy (Fig. 1c) , despite markedly increased serum IGF-I and IGFBP-3 concentrations. Samples for further analysis of IGF1R protein expression and functions were, unfortunately, not available. 
FACS of Cell-Surface IGF1R on Live Primary Cells
An IGF1R haploinsufficiency state was indicated for each of our 3 probands. We had previously demonstrated that IGF1R haploinsufficiency due to nonsense-mediated mRNA decay, IGF1R c.3348_3366dup [11] , and a hypomorphic IGF1R p.E121K/E234K compound heterozygous mutation [6] , resulted in significantly reduced total IGF1R protein expressions with concomitant reduction in IGF-I-induced signaling. To assess if IGF1R expression was similarly altered in our present patients, we employed flow cytometry analysis by FACS of live cells derived from P1 and P2, probing for the presence of cell-surface IGFIR (Fig. 3) . Unlike methods for assessing total IGF1R expression, FACS analysis provides relative quantitation of expressed IGF1R that had translocated appropriately to the cell surface, thus reflecting in vivo availability of IGF1R.
The geometric mean fluorescence intensities (MFI) emitted by anti-IGF1R-PE-probed live dermal fibroblasts from P1 and P2 were compared to the MFI from our panel of normal (C1) and previously characterized IGF1R-deficient fibroblasts. Fibroblasts carrying the previously described IGF1R c.3348_3366dup or IGF1R p.E121K/ E234K mutations had basal MFI that were significantly reduced (46 ± 9% SD and 37 ± 4% SD, respectively) relative to untreated C1 (arbitrarily assigned a MFI of 100%; Fig. 3a) . The MFI of fibroblasts carrying the heterozygous IGF1R p.R877* variant (P1) or IGF1R CNV (P2) were similarly reduced at 39 ± 9% SD and 46 ± 13% SD, respectively (Fig. 3a) , and comparable to our proven IGF1R haploinsufficient and hypomorphic cells. When C1 and IGF1R haploinsufficient fibroblasts (c.3348_3366dup, p.R877*, or IGF1R CNV) were treated with IGF-I (100 ng/mL, 24 h), the emitted MFI were found to be reproducibly, and comparably, further reduced (Fig. 3a, b) . In contrast, compound heterozygous IGF1R p.E121K/ E234K fibroblasts demonstrated poor responsiveness to IGF-I (Fig. 3a) . Altogether, the results suggest that availability of cell-surface wild-type IGF1R significantly decreases after exposure to IGF-I, possibly due to ligandreceptor internalization, and this phenomenon was observed for normal as well as IGF1R haploinsufficient cells.
We had previously shown that a deficiency in IGF1R could be detected by FACS analysis of PBMCs [18] , a biological sample much more readily accessible than primary dermal fibroblasts established from skin biopsies. Since we had access to whole blood samples from P2 and his parents, FACS analysis of isolated live PBMCs for cellsurface IGF1R was performed to determine whether there might be variations in IGF1R expression, depending on cell type. Of note, the mother of P2 carries the same IGF1R CNV while the father was wild-type for the CNV. As shown in Figure 3c and d, the fluorescence intensity emitted by anti-IGF1R-PE-labeled PBMCs from P2 (52 ± 6% SD) and the mother (50 ± 7% SD) were similarly and markedly reduced when compared to both normal PBMCs and PBMCs from the father (87 ± 18% SD). For all PBMC samples analyzed, exposure to 50 ng/mL IGF-I for 1 h was sufficient to further reduce detectable cellsurface IGF1R (Fig. 3d) .
IGF-I-Induced IGF1R Signaling
To confirm that IGF1R haploinsufficiency in P1 and P2 correlated with reduced IGF1R signaling, primary dermal fibroblast cultures were stimulated with 100 ng/ mL of IGF-I for 20 min and phosphorylation of Thr308 on AKT, phospho-T 308 -AKT, assessed. Primary fibroblasts from both patients demonstrated decreased T 308 -AKT phosphorylation compared to C1 cells (Fig. 3e) .
Discussion
The importance of having 2 intact alleles of the IGF1R gene for normal intrauterine and postnatal growth is supported by the recognition of IGF1R haploinsufficiency as causal of pre-and postnatal growth retardation [8] . IGF1R haploinsufficiency can be the consequence of allelic loss of IGF1R due to chromosomal 15q26 deletions (first reported in 1991 [20] ; P2 and P3 in this report) or due to specific allelic IGF1R mutations that abrogate mRNA [11] or protein expression (P1 in this report). Here, we demonstrated that cell-surface IGF1R levels were reduced by at least 50% when live primary cells, confirmed genetically for IGF1R haploinsufficiency, were analyzed by FACS, and this reduction correlated to reduced IGF-I-induced IGF1R signaling. This implies that biallelic protein expression is critical for maintaining normal cell-surface IGF1R availability and function. These results also serve to highlight FACS analysis of primary cells derived from patients as an efficient method for evaluating IGF1R haploinsufficiency. Future studies will include verifying the uniformity of cell-surface IGF1R expression in the different subpopulations of normal PBMCs and whether expression might be influenced by age or gender.
Cell-surface IGF1R availability was indistinguishable amongst our IGF1R haploinsufficient patients, who shared features of SGA and poor postnatal growth despite normal to markedly elevated serum IGF-I concentrations. Other clinical and biochemical features, however, including responsiveness to rhGH therapy [8, 21] highly variable as has been previously reported [8, 22] . Both P1, carrying the heterozygous nonsense variant IGF1R p.R877*, and her father who carried the same variant, exhibited mild short stature (height SDS of -2.06 and -1.93, respectively) but had no other apparent phenotypic anomalies. The p.R877* nonsense mutation abrogated C879-mediated disulfide formation necessary for a functional IGF1R α-β monomer, which, together with a lack of detectable truncated p.R877* peptides (either cell-associated or secreted, data not shown), support their IGF1R haploinsufficiency state. Of note, the p.R877* variant (c.2629C>T, rs150221450), although not novel, is extremely rare as it was found in only 1 in 121,408 IGF1R alleles sequenced (NCBI dbSNP and ExAC databases) with clinical significance unknown. Our results provide strong evidence that this variant is likely to be the underlying cause of the mild short stature observed in this family.
In contrast to P1, P2 and P3 exhibited pronounced short stature and other phenotypic anomalies. Both probands carry IGF1R CNV, although P3, who carried a significantly larger chromosomal 15q26 deletion (4.5 Mb), was the more severely affected of the two, with a phenotype consistent with chromosome 15q26-qter deletion syndrome (MIM 612626) including cardiac defects, facial dysmorphism, auditory processing disorder, crowded dentition, and ocular hypertelorism. P2, in addition to carrying a maternally inherited IGF1R CNV, was also diagnosed with NF-1, but his growth abnormalities were not typical of those more commonly associated with NF-1 (macrocrania, reduced pubertal growth spurt in boys, and, in some, overweight status) [23] . Interestingly, it remains unclear why the mother of P2, who was IGF1R haploinsufficient by both genetic and functional assessments, was of normal stature. Altogether, the diverse spectrum of presentations by P2 and P3 may be consequences of CNV involving contiguous genes/chromosomal regions in addition to the IGF1R gene [22, [24] [25] [26] .
The inability of targeted Sanger sequencing or WES variant analysis to detect gross allelic deletions of IGF1R illustrates the importance of including CNV analysis in the initial evaluation of children who present with preand postnatal growth failure in the presence of normal to elevated serum IGF-I concentrations suggestive of IGF1R insufficiency. Chromosomal IGF1R deletions can be readily identified by conventional methods, including karyotype (for large deletions), chromosomal microarrays, and SNP genotyping arrays, as was performed for P2, although it is of note that the 0.282-Mb deletion was on the border of resolution for microarray analysis. Multiplex ligation probe amplification applications have also detected IGF1R CNV in affected patients [13, 27] . The limited resolution of all these methods, however, requires additional methodologies to delineate boundaries of CNV. For P3, we leveraged existing WES data to serve as a basis for CNV discovery, an application that provides much finer resolution (less than 1 kb) than conventional CNV methods. WES data generated from P3 and her parents had not identified candidate single nucleotide variations of significance, but through XHMM analysis [17] , which is a relatively sensitive and specific algorithm for detecting rare, large CNV [28] [29] [30] , 27 CNV in P3 were uncovered. Of these, only 1, a 4.492-Mb heterozygous chromosome 15 deletion that spans 28 genes, including the entire IGF1R gene, was unique to P3. Our finding of an IGF1R deletion in P3, therefore, supports the efficacy and efficiency of using exome sequencing for both variant and CNV detection, and is in line with the proposed "exome-first" paradigm for clinical investigations of genetic defects [28] . While successfully applied to our present case, additional algorithm refinement and testing will likely be necessary before these approaches can be widely Fig. 3 . IGF1R expression and functional analysis. FACS analysis of cell-surface IGF1R, labeled by PE-conjugated anti-human IGF1R-alpha antibody, on live primary cells derived from affected patients. a The geometric mean fluorescence intensity (MFI, y axis) emitted by labeled primary fibroblasts, untreated (black bars) and IGF-I treated (100 ng/mL, 24 h; white bars), is presented relative to MFI of normal, untreated, C1 fibroblasts, which was arbitrarily assigned a value of 100%. Experiments were performed at least 3 independent times, each time in duplicates. P1: R877X; P2: 15q26. applied clinically in the genetic workup for patients with rare diseases.
Finally, therapeutic options for patients with IGF1R haploinsufficiency are currently limited to rhGH, as the majority of these patients are born SGA without catch-up growth, a clinical condition approved for rhGH therapy. While long-term treatment, starting at a young age, has been successful for improving stature for some patients [5, 13, 21] , including for P1 who had mild short stature, overall responsiveness has been highly variable [8, 21] . P3, for example, improved height by only 1 SD with 3 years of rhGH therapy, reaching a height SDS of -4.1 at age 9.5 years, and no catch-up growth was reported for the patient with IGF1R haploinsufficiency due to the c.3348_3366dup19 mutation [11] . P2 was not treated with rhGH because of concerns about potential impact on his NF-1 condition. The reason(s) for variable responsiveness to rhGH remains to be fully elucidated, with treatment tempered by concerns of extreme elevations of serum IGF-I concentrations, as was observed for P1 and P3. Continued monitoring of serum IGF-I and adjustment of dosage is highly recommended.
In summary, the molecular basis of IGF1R haploinsufficiency can be established by multiple methods, including utilizing genome-wide data for uncovering IGF1R CNV, as demonstrated in this report. Our application highlights how genome-wide data can serve the dual purpose of variant and CNV discovery. FACS analyses of live primary cells derived from IGF1R haploinsufficient patients supported the genetic findings and, moreover, provide valuable insights into cell-surface receptor availability critical for growth-promoting responses. Further investigations are necessary to delineate mechanisms of how seemingly comparable IGF1R availability can result in a wide spectrum of clinical phenotypes and variable responsiveness to rhGH therapy. 
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